Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAE1 | Q9UBE0 | 10/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 10/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | CASP1 | P29466 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | POLB | P06746 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | NSD2 | O96028 | 2/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 1.00 |
| ▸ | CASP6 | P55212 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15256873 | 0.93 | SAE1 (0.87) | SAE1UBA2HSD17B10KDM4ECASP1 | |
| SCHEMBL4787152 | 0.92 | SAE1 (0.85) | SAE1UBA2HSD17B10KDM4ECASP1 | |
| SCHEMBL4787545 | 0.92 | SAE1 (1.00) | SAE1UBA2HSD17B10KDM4ECASP1 | |
| SCHEMBL4787907 | 0.89 | SAE1 (0.94) | SAE1UBA2HSD17B10KDM4ECASP1 | |
| SCHEMBL15256907 | 0.89 | SAE1 (1.00) | SAE1UBA2HSD17B10KDM4ECASP1 | |
| SCHEMBL6980462 | 0.86 | SAE1 (1.00) | SAE1UBA2HSD17B10KDM4ECASP1 | |
| SCHEMBL15256874 | 0.86 | SAE1 (1.00) | SAE1UBA2HSD17B10KDM4ECASP1 | |
| SCHEMBL4785129 | 0.85 | CASP1 (0.75) | SAE1UBA2HSD17B10KDM4ECASP1 | |
| SCHEMBL15256865 | 0.84 | SAE1 (0.86) | SAE1UBA2HSD17B10KDM4ECASP1 | |
| SCHEMBL8163981 | 0.84 | KDM4E (0.73) | SAE1UBA2HSD17B10KDM4ECASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008115259-A2 | DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-9073941-B2 | Compounds and methods for treating tuberculosis infection | ACADEMIA SINICA (TW) | 2015-07-07 | — | — | US | disclosed |
| US-9045483-B2 | Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines | CITY OF HOPE (US) | 2015-06-02 | — | — | US | disclosed |
| US-9045483-B2 | Inhibition of small ubiquitin-like modifier enzymes with substituted pyrrolo[2,3-b]quinoxalines | CITY OF HOPE (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | Sanford-Burnham Medical Research Institute at Lake Nona (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | Sanford-Burnham Medical Research Institute at Lake Nona (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| WO-2012064897-A2 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS FOR THEIR USE | CHEN YUAN (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245032-A1 | BICYCLIC AND TRICYCLIC INHIBITORS OF SUMOYLATION ENZYMES AND METHODS OF THEIR USE | SUMO1, SUMO2, SAE1 | SAE1 3/4885UBA2 4/4885HSD17B10 1143/4885 |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | TALDO1, PGD, DLD | SAE1 2017/4885UBA2 2986/4885HSD17B10 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.